Sanofi CEO Debuts With Sobering News
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi ‘s 2008 financials were solid, but future growth is a challenge.
You may also be interested in...
Solvay Analyzing “Various Options” For Its Pharma Unit
Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.
Solvay Analyzing “Various Options” For Its Pharma Unit
Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.
Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis
Deal could complicate venture investors' exit, though Portola thinks not – as another would-be partner eyes second lead product.